Clinical trial
Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)
NCT00222170 · University of Kansas, Other · Completed
Key facts
| NCT number | NCT00222170 |
|---|---|
| Title | Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD) |
| Official title | Esophagoprotection by Rabeprazole Mediated by Restoration of an Impairment in Esophageal Mucin Production: Its Potential Therapeutic Benefit in Patients With Gastroesophageal Reflux Disease (GERD) |
| Lead sponsor | University of Kansas, Other |
| Collaborators | PriCara, Unit of Ortho-McNeil, Inc. Industry Eisai Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Reflux |
| Intervention type | Drug |
| Interventions | Rabeprazole |
| Enrollment | 24 |
| Start date | May 1, 2005 |
| Completion | May 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | May 8, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: